blood-group-a-trisaccharide and Anemia

blood-group-a-trisaccharide has been researched along with Anemia* in 2 studies

Other Studies

2 other study(ies) available for blood-group-a-trisaccharide and Anemia

Article	Year
Complete disappearance of ABO antigen-a cause of ABO discrepancy. Transfusion, 2018, Volume: 58, Issue:1 Topics: ABO Blood-Group System; Adolescent; Agglutination Tests; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Group Incompatibility; Blood Grouping and Crossmatching; Coombs Test; Cytarabine; Daunorubicin; Erythrocyte Transfusion; Fatal Outcome; Female; Humans; Leukemia, Erythroblastic, Acute; Oligosaccharides; Oligosaccharides, Branched-Chain; Plant Lectins; Platelet Transfusion; Sepsis	2018
Severe immune haemolysis in a group A recipient of a group O red blood cell unit. Transfusion medicine (Oxford, England), 2003, Volume: 13, Issue:4 Haemolysis caused by passive ABO antibodies is a rare transfusional complication. We report a case of severe haemolytic reaction in a 38-year-old man (blood group A) with lymphoma who had received one red blood cell (RBC) unit group O. After transfusion of 270 mL, the patient experienced fever, dyspnoea, chills and back pain. On the following morning he was icteric and pale. Haptoglobin was inferior to 5.8 mgdL(-1), haemoglobin was not increased and lactate dehydrogenase was elevated. Haemolysis was evident on observation of the patient's post-transfusion samples. The recipient's red cells developed a positive direct antiglobulin test and Lui elution showed anti-A coated the cells. Fresh donor serum had an anti-A titre of 1024, which was not reduced by treating the serum with dithiothreitol. Donor isoagglutinin screening has been determined by microplate automated analyser and showed titre higher than 100. Physicians should be aware of the risk of haemolysis associated with ABO-passive antibodies. There is generally no agreement justifying the isoagglutinin investigation prior to transfusion. However, automated quantitative isoagglutinin determination could be part of the modern donor testing process, mainly in blood banks where identical ABO group units (platelets or phenotyped RBCs) are not available owing to limited supply. Topics: ABO Blood-Group System; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Donors; Blood Group Incompatibility; Cisplatin; Cytarabine; Dexamethasone; Erythrocyte Transfusion; Fever; Hemolysis; Humans; Immunization, Passive; Isoantibodies; Jaundice; Lymphoma, Non-Hodgkin; Male; Oligosaccharides; Oligosaccharides, Branched-Chain; Pain	2003

Article

Year

Complete disappearance of ABO antigen-a cause of ABO discrepancy.

Transfusion, 2018, Volume: 58, Issue:1

Topics: ABO Blood-Group System; Adolescent; Agglutination Tests; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Group Incompatibility; Blood Grouping and Crossmatching; Coombs Test; Cytarabine; Daunorubicin; Erythrocyte Transfusion; Fatal Outcome; Female; Humans; Leukemia, Erythroblastic, Acute; Oligosaccharides; Oligosaccharides, Branched-Chain; Plant Lectins; Platelet Transfusion; Sepsis

2018

Severe immune haemolysis in a group A recipient of a group O red blood cell unit.

Transfusion medicine (Oxford, England), 2003, Volume: 13, Issue:4

Haemolysis caused by passive ABO antibodies is a rare transfusional complication. We report a case of severe haemolytic reaction in a 38-year-old man (blood group A) with lymphoma who had received one red blood cell (RBC) unit group O. After transfusion of 270 mL, the patient experienced fever, dyspnoea, chills and back pain. On the following morning he was icteric and pale. Haptoglobin was inferior to 5.8 mgdL(-1), haemoglobin was not increased and lactate dehydrogenase was elevated. Haemolysis was evident on observation of the patient's post-transfusion samples. The recipient's red cells developed a positive direct antiglobulin test and Lui elution showed anti-A coated the cells. Fresh donor serum had an anti-A titre of 1024, which was not reduced by treating the serum with dithiothreitol. Donor isoagglutinin screening has been determined by microplate automated analyser and showed titre higher than 100. Physicians should be aware of the risk of haemolysis associated with ABO-passive antibodies. There is generally no agreement justifying the isoagglutinin investigation prior to transfusion. However, automated quantitative isoagglutinin determination could be part of the modern donor testing process, mainly in blood banks where identical ABO group units (platelets or phenotyped RBCs) are not available owing to limited supply.

Topics: ABO Blood-Group System; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Donors; Blood Group Incompatibility; Cisplatin; Cytarabine; Dexamethasone; Erythrocyte Transfusion; Fever; Hemolysis; Humans; Immunization, Passive; Isoantibodies; Jaundice; Lymphoma, Non-Hodgkin; Male; Oligosaccharides; Oligosaccharides, Branched-Chain; Pain

2003